Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517837 | 1.00 | IDO1 (0.49) | IDO1NAMPTKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2515813 | 0.94 | IDO1 (0.46) | IDO1NAMPT | |
| Trifluoroacetic Acid SCHEMBL2515807 | 0.94 | IDO1 (0.46) | IDO1NAMPT | |
| SCHEMBL2519682 | 0.91 | IDO1 (0.49) | IDO1NAMPTKCNH2 | |
| SCHEMBL2519685 | 0.91 | IDO1 (0.49) | IDO1NAMPTKCNH2 | |
| SCHEMBL2518332 | 0.90 | IDO1 (0.49) | IDO1NAMPTKCNH2 | |
| SCHEMBL2518328 | 0.90 | IDO1 (0.49) | IDO1NAMPTKCNH2 | |
| SCHEMBL14237529 | 0.89 | IDO1 (0.48) | IDO1NAMPTKCNH2 | |
| SCHEMBL2516298 | 0.89 | IDO1 (0.48) | IDO1NAMPTKCNH2 | |
| SCHEMBL12053084 | 0.89 | IDO1 (0.43) | IDO1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030006-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2018-02-01 | — | — | US | claimed |
| EP-3085697-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Holdings Corporation (US) | 2016-10-26 | — | — | EP | claimed |
| EP-2559690-B1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE HOLDINGS CORP (US) | 2016-03-30 | — | — | EP | claimed |
| US-8846726-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2014-09-30 | — | — | US | claimed |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2013-05-16 | — | — | US | claimed |
| EP-2559690-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | Incyte Corporation (US) | 2013-02-20 | — | — | EP | claimed |
| US-8372870-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer | INCYTE CORPORATION (US) | 2013-02-12 | — | — | US | claimed |
| EP-1879573-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2012-12-19 | — | — | EP | claimed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | claimed |
| US-8034953-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2011-10-11 | — | — | US | claimed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | claimed |
| EP-3085697-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Holdings Corporation (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2559690-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | Incyte Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030006-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885NAMPT 219/4885KCNH2 3793/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885NAMPT 219/4885KCNH2 3793/4885 |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885NAMPT 219/4885KCNH2 3793/4885 |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885NAMPT 219/4885KCNH2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.